Skip to content
Global Access Atlas

Market access pathways by country

Explore how an innovative medicine moves from approval to patient access.

Selected market

Malaysia

NPRA evaluates the product for the Drug Control Authority. Access in the public sector then depends on a separate Ministry of Health Medicines Formulary submission, pharmacoeconomic review and implementation.

NPRA / DCA
MOH Pharmacy Programme
MOH committees
MOH
MOH facilities
5 decision nodes13 cited sources

For education only — not regulatory, pricing or legal advice.

About the content and how to use it